S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial
In this study of South Korean and Japanese patients (n=711), oral TAS-118 (S-1 plus leucovorin) and oxaliplatin was associated with a small improvement in overall survival versus S-1 plus cisplatin (median 16.0 v 15.1 months; HR 0.83; 95% CI 0.69–0.99; p=0.039).
Source:
The Lancet Oncology
SPS commentary:
A related comment notes that the overall benefit extended to patients with diffuse-type histology, which is usually associated with chemo-refractoriness and poor prognosis. However the observed overall survival benefit was small and there was no companion quality of life study. The authors also comment that TAS-118 plus oxaliplatin should be tested in non-Asian patients, although it is known that S-1 is not equally tolerated in non-Asian patients and Asian patients.